BENGALURU, May 19 (Reuters) – Abbott India Ltd (ABOT.NS) reported a 9.5% bounce in fourth-quarter revenue on Friday, helped by sturdy gross sales in its mainstay prescribed drugs section.

Profit for the corporate, which makes ibuprofen pain-reliever beneath the model identify Brufen, rose to 2.31 billion rupees ($28.3 million) within the three months ended March 31, from 2.11 billion rupees a 12 months in the past, the corporate said in an trade submitting.

For additional outcomes highlights, click on

WHY IT MATTERS

Abbot India, for which pharmaceutical is the only income generator, develops and distributes over 600 merchandise in India, together with nutritional vitamins, anti-allergic medication and client care. The native unit of U.S. healthcare firm Abbott Laboratories (ABT.N) reported double-digit development in web earnings within the final two quarters, helped by a gentle decline in working bills.

Earlier this week, rival Pfizer Ltd (PFIZ.NS) reported a 3.1% enhance in fourth-quarter revenue on decrease uncooked materials bills, whereas GlaxoSmithKline Pharmaceuticals Ltd (GLAX.NS) posted an 8.6% fall in pre-tax revenue.

PEER COMPARISON

* Mean of analysts’ scores standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell

** Ratio of the inventory’s final near analysts’ imply worth goal; a ratio above 1 means the inventory is buying and selling above the PT

JAN-MARCH STOCK PERFORMANCE

— All knowledge from Refinitiv

— $1 = 81.7800 Indian rupees

Reporting by Rama Venkat in Bengaluru; Editing by Sherry Jacob-Phillips and Dhanya Ann Thoppil

Our Standards: The Thomson Reuters Trust Principles.